Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2024Open Access

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

Shaji KumarShaji KumarMayo ClinicMRMatthew J. ReesMayo ClinicAMAytaj MammadzadehSUNY Downstate Health Sciences University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kumar et al. (2024) studied this question.

synapsesocial.com/papers/68e6e752b6db643587662332https://doi.org/10.21203/rs.3.rs-4254335/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY2023 · 31 citations
  2. 2Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma2019 · 1,787 citations
  3. 3LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.2023 · 58 citations
  4. 4Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-12022 · 48 citations
  5. 5Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 12011 · 1,047 citations